The burgeoning popularity of retatrutide, initially for diabetes , is creating significant buzz within the UK , prompting a notable shift in medication trends. Availability these compounds remains a complex situation , with National Health Service coverage currently limited and independent providers offering therapy at a higher cost . Concerns are